Royalty Pharma (NASDAQ:RPRX) reported quarterly sales of $576.00 million which beat the analyst consensus estimate of $556.79 million by 3.45 percent. This is a 0.70 percent increase over sales of $572.00 million the same period last year.
Related Posts
Morgan Stanley Maintains Equal-Weight on 8×8, Lowers Price Target to $4
Morgan Stanley analyst Meta Marshall maintains 8x8 (NYSE:EGHT) with a Equal-Weight and lowers the price target from $6.5 to $4.
UBS Sees 22% Upside In Autohome – Read Why
UBS analyst Paul Gong initiated coverage of Autohome Inc (NYSE:ATHM) with a Neutral rating and a $38 price target, implying a 22.3% upside.…
Here’s How Much $100 Invested In Okta 5 Years Ago Would Be Worth Today
Okta (NASDAQ:OKTA) has outperformed the market over the past 5 years by 19.94% on an annualized basis producing an average annual return of 31.65%. Currently, Okta has a market capitalization of $16.03 billion.